Jpmorgan Chase & CO Aurinia Pharmaceuticals Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 701,502 shares of AUPH stock, worth $8.31 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
701,502
Previous 927,298 24.35%
Holding current value
$8.31 Million
Previous $8.33 Million 32.27%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$7.55 - $8.77 $1.7 Million - $1.98 Million
-225,796 Reduced 24.35%
701,502 $5.64 Million
Q4 2024

Feb 12, 2025
BUY
$6.75 - $10.44 $2.87 Million - $4.43 Million
424,482 Added 84.42%
927,298 $8.33 Million
Q3 2024

Dec 26, 2024
SELL
$5.32 - $7.33 $22,439 - $30,917
-4,218 Reduced 0.83%
502,816 $3.69 Million
Q3 2024

Nov 08, 2024
SELL
$5.32 - $7.33 $22,439 - $30,917
-4,218 Reduced 0.83%
502,816 $3.69 Million
Q2 2024

Dec 26, 2024
BUY
$4.81 - $5.78 $20,288 - $24,380
4,218 Added 0.84%
507,034 $2.9 Million
Q2 2024

Aug 12, 2024
BUY
$4.81 - $5.78 $957,685 - $1.15 Million
199,103 Added 64.66%
507,034 $2.9 Million
Q1 2024

Dec 26, 2024
SELL
$4.93 - $9.31 $960,783 - $1.81 Million
-194,885 Reduced 38.76%
307,931 $1.54 Million
Q1 2024

May 10, 2024
BUY
$4.93 - $9.31 $437,922 - $826,988
88,828 Added 40.54%
307,931 $1.54 Million
Q4 2023

Dec 26, 2024
SELL
$7.13 - $9.49 $2.02 Million - $2.69 Million
-283,713 Reduced 56.42%
219,103 $1.97 Million
Q4 2023

Feb 12, 2024
SELL
$7.13 - $9.49 $67,136 - $89,357
-9,416 Reduced 4.12%
219,103 $1.97 Million
Q3 2023

Nov 14, 2023
SELL
$7.77 - $12.27 $1.27 Million - $2.01 Million
-163,899 Reduced 41.77%
228,519 $1.78 Million
Q2 2023

Aug 11, 2023
BUY
$8.96 - $11.69 $1.62 Million - $2.11 Million
180,476 Added 85.15%
392,418 $3.8 Million
Q1 2023

May 18, 2023
BUY
$5.94 - $11.27 $1.02 Million - $1.94 Million
172,363 Added 435.49%
211,942 $2.32 Million
Q1 2023

May 11, 2023
SELL
$5.94 - $11.27 $602,500 - $1.14 Million
-101,431 Reduced 71.93%
39,579 $433,000
Q4 2022

Feb 13, 2023
BUY
$4.11 - $8.14 $268,983 - $532,730
65,446 Added 86.61%
141,010 $610,000
Q3 2022

Nov 14, 2022
BUY
$6.66 - $12.39 $21,911 - $40,763
3,290 Added 4.55%
75,564 $568,000
Q2 2022

Aug 11, 2022
BUY
$8.95 - $12.8 $578,608 - $827,507
64,649 Added 847.86%
72,274 $726,000
Q1 2022

May 11, 2022
BUY
$10.05 - $22.48 $41,345 - $92,482
4,114 Added 117.17%
7,625 $94,000
Q4 2021

Feb 10, 2022
SELL
$17.78 - $33.08 $44,432 - $82,666
-2,499 Reduced 41.58%
3,511 $80,000
Q3 2021

Nov 12, 2021
BUY
$10.93 - $23.55 $65,689 - $141,535
6,010 New
6,010 $133,000

Others Institutions Holding AUPH

# of Institutions
245
Shares Held
62.5M
Call Options Held
1.03M
Put Options Held
666K
View Full List

About Aurinia Pharmaceuticals Inc.

AUPH Quotes by TradingView
  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.68B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email